AngioDynamics Raises FY2026 Adj EPS Guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) vs $(0.29) Est; Raises FY2026 Sales Guidance from $312.000M-$314.000M to $313.500M-$315.500M vs $312.881M Est

AngioDynamics (NASDAQ:ANGO) raises FY2026 Adj EPS guidance from $(0.33)-$(0.23) to $(0.30)-$(0.23) vs $(0.29) analyst estimate. Raises FY2026 sales outlook from $312.000 million-$314.000 million to $313.500 million-$315.500 million vs $312.881 million estimate.